CA Patent

CA2805958A1 — Greater utility with thyroid hormone

Assigned to Individual · Expires 2011-02-10 · 15y expired

What this patent protects

Formulations and delivery systems that include a thyroid hormone active agent consisting essentially of T4 should reduce fluctuations in delivery of thyroid hormone.

USPTO Abstract

Formulations and delivery systems that include a thyroid hormone active agent consisting essentially of T4 should reduce fluctuations in delivery of thyroid hormone.

Drugs covered by this patent

Unithroid (LEVOTHYROXINE SODIUM) · Fresenius Kabi

Patent Metadata

Patent number: CA2805958A1
Jurisdiction: CA
Classification: —
Expires: 2011-02-10
Drug substance claim: No
Drug product claim: No
Assignee: Individual
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.